DOI QR코드

DOI QR Code

Heparanase mRNA and Protein Expression Correlates with Clinicopathologic Features of Gastric Cancer Patients: a Meta-analysis

  • Li, Hai-Long (School of Medicine Technology, Gansu University of Traditional Chinese Medicine) ;
  • Gu, Jing (Key Laboratory of Traditional Chinese Herbs and Prescription Innovation and Transformation of Gansu Province, Gansu University of Traditional Chinese Medicine) ;
  • Wu, Jian-Jun (School of Public Health Institute, Gansu University of Traditional Chinese Medicine) ;
  • Ma, Chun-Lin (Key Laboratory of Traditional Chinese Herbs and Prescription Innovation and Transformation of Gansu Province, Gansu University of Traditional Chinese Medicine) ;
  • Yang, Ya-Li (School of Medicine Technology, Gansu University of Traditional Chinese Medicine) ;
  • Wang, Hu-Ping (Key Laboratory of Traditional Chinese Herbs and Prescription Innovation and Transformation of Gansu Province, Gansu University of Traditional Chinese Medicine) ;
  • Wang, Jing (School of Medicine Technology, Gansu University of Traditional Chinese Medicine) ;
  • Wang, Yong (School of Medicine Technology, Gansu University of Traditional Chinese Medicine) ;
  • Chen, Che (School of Medicine Technology, Gansu University of Traditional Chinese Medicine) ;
  • Wu, Hong-Yan (Key Laboratory of Traditional Chinese Herbs and Prescription Innovation and Transformation of Gansu Province, Gansu University of Traditional Chinese Medicine)
  • Published : 2016.01.11

Abstract

Background: Heparanase is believed to be involved in gastric carcinogenesis. However, the clinicopathologic features of gastric cancer with high heparanase expression remain unclear. Aim : The purpose of this study was to comprehensively and quantitatively summarize available evidence for the use of heparanase mRNA and protein expression to evaluate the clinicopathological associations in gastric cancer in Asian patients by meta-analysis. Materials and Methods: Relevant articles listed in MEDLINE, CNKI and the Cochrane Library databases up to MARCH 2015 were searched by use of several keywords in electronic databases. A meta-analysis was performed to clarify the impact of heparanase mRNA and protein on clinicopathological parameters in gastric cancer. Combined ORs with 95%CIs were calculated by Revman 5.0, and publication bias testing was performed by stata12.0. Results: A total of 27 studies which included 3,891 gastric cancer patients were combined in the final analysis. When stratifying the studies by the pathological variables of heparanase mRNA expression, the depth of invasion (633 patients) (OR=4.96; 95% CI=2.38-1.37; P<0.0001), lymph node metastasis (639 patients) (OR=6.22; 95%CI=2.70-14.34, P<0.0001), and lymph node metastasis (383 patients) (OR=6.85; 95% CI=2.04-23.04; P=0.002) were all significant. When stratifying the studies by the pathological variables of heparanase protein expression, this was the case for depth of invasion (1250 patients) (OR=2.76; 95% CI=1.52-5.03; P=0.0009), lymph node metastasis (1178 patients) (OR=4.79 ; 95% CI=3.37-6.80, P<0.00001), tumor size (727 patients) (OR=2.06 ; 95% CI=1.31-3.23; P=0.002) (OR=2.61; 95% CI=2.09-3.27; P=0.000), and TNM stage (1233 patients) (OR=6.85; 95% CI=2.04-23.04; P=0.002). Egger's tests suggested publication bias for depth of invasion, lymph node metastasis, lymph node metastasis and tumor size of heparanase mRNA and protein expression. Conclusions: This meta-analysis suggests that higher heparanase expression in gastric cancer is associated with clinicopathologic features of depth of invasion, lymph node metastasis and TNM stage at mRNA and protein levels, and of tumor size only at the protein level. Egger's tests suggested publication bias for these clinicopathologic features of heparanase mRNA and protein expression, and which may be caused by shortage of relevant studies. As a result, although abundant reports showed heparanase may be associated with clinicopathologic features in gastric cancer, this meta-analysis indicates that more strict studies were needed to evaluate its clinicopathologic significance.

Keywords

Gastric cancer;heparanase;clinicopathologic features;meta-analysis

References

  1. Liu ZH, An ZhQ, Li EJ, et al (2004). The expressions of heparanase, bFGF fibroblast growth factor expression in gastric cancer with their effects on angiogenesis and tumor progression. Sichuan J Physiological Sci 106-8.
  2. Ma XM, Sun Q, Ren MJ, et al (2007). The expressions of heparanase and NF kappa B in gastric cancer and with the clinical pathological features and vascular formation. J China Histochemistry Cytochemistry, 12-8.
  3. Qi YQ, Si JL, Li WL, et al (2010). The expressions of Syndecan-1 and HPA-1 mRNA in gastric cancer tissue and its relationship with invasion and metastasis of gastric cancer. Chinese J Cancer, 110-5.
  4. Ru GQ, Zhao ZHS, Tang QL, et al (2006). The mRNA expressions of Syndecan-1 and heparanase in gastric cancer and its relationship with metastasis and prognosis of gastric cancer. Chinese J Surg, 1062-4.
  5. Su N, Chen B, Chen JZH, et al (2009). The expression of heparanase in gastric cancer and hepatocellular carcinoma and its clinical significance. J Practical Med, 1207-9.
  6. Cai YG, Fang DC, Yang SM, et al (2004). [Increased expression of heparanase mRNA is correlated with metastasis of gastric carcinoma and is probably correlated with c-met protein]. Zhonghua Yi Xue Za Zhi, 84, 974-8.
  7. Chen JQ, Zhan WH, He YL, et al (2004a). Expression of heparanase gene, CD44v6, MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas. World J Gastroenterol, 10, 776-82. https://doi.org/10.3748/wjg.v10.i6.776
  8. Zheng L, Jiang G, Mei H, et al (2010). Small RNA interferencemediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells. BMC Cancer, 10, 33. https://doi.org/10.1186/1471-2407-10-33
  9. Zheng L, Weng M, Qi M, et al (2012). Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis. J Cancer Res Clin Oncol, 138, 163-72. https://doi.org/10.1007/s00432-011-1088-8
  10. Zheng LD, Jiang GS, Pu JR, et al (2009). Stable knockdown of heparanase expression in gastric cancer cells in vitro. World J Gastroenterol, 15, 5442-8. https://doi.org/10.3748/wjg.15.5442
  11. Cai YG, Fang DC, Yang ShM, et al (2004). The significance of the expression of heparanase mRNA in gastric cancer tissues. J Fourth Military Med University, 909-11.
  12. Chen Bo (2009). Expressions of heparanase and matrix metalloproteinase-9 in gastric cancer and its clinical significance. J Hainan Med College, 852-4
  13. Huang ZHQ, Liu SH, Chen SL, et al (2008). The study of HPA, bFGF and FGFR-2 expressions in gastric cancer tissue. J Modern Chinese Western Integrated Med. 3565, 6-75.
  14. Jiang WH, Zhu XM, Yang ZHP, et al (2011). The expression of heparanase in gastric cancer tissue with its clinical pathological features. Chinese J Gerontol, 3262-3.
  15. Li Tao, QJ (2012). The expression and significance of integrin alpha 5 beta 1 and heparanase in gastric carcinoma. Guangdong Med. 2974-6.
  16. Liang H, Zhang L, Zhang Xu (2009). The expression and clinical significance of HPA in gastric cancer tissues. Health Vocational Educat, 102-3.
  17. Liu Y, Yang HG, Zuo LF (2007). The expression of heparanase in gastric cancer and DNA content quantitative research by flow cytometry. J Med Res, 40-3.
  18. Chen JQ, Zhan WH, He YL, et al (2004b). [Relationship between heparanase mRNA expression in human gastric cancer and its clinicopathological features]. Zhonghua Zhong Liu Za Zhi, 26, 609-11.
  19. Cheng C, Lu X, Wang G, et al (2010). Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS, 118, 855-63. https://doi.org/10.1111/j.1600-0463.2010.02673.x
  20. Han Y, Xue XF, Shen HG, et al (2014). Prognostic significance of Beclin-1 expression in colorectal cancer: a meta-analysis. Asian Pac J Cancer Prev, 15, 4583-7. https://doi.org/10.7314/APJCP.2014.15.11.4583
  21. Inoue H, Mimori K, Utsunomiya T, et al (2001). Heparanase expression in clinical digestive malignancies. Oncol Rep, 8, 539-42.
  22. Liu WJ, Tan XH, Guo BP, et al (2013). Associations between RASSF1A promoter methylation and NSCLC: a metaanalysis of published data. Asian Pac J Cancer Prev, 14, 3719-24. https://doi.org/10.7314/APJCP.2013.14.6.3719
  23. Liu Y, Lv DL, Duan JJ, et al (2014). ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and metaanalysis. BMC Cancer, 14, 444. https://doi.org/10.1186/1471-2407-14-444
  24. Masola V, Secchi MF, Gambaro G, et al (2014). Heparanase as a target in cancer therapy. Curr Cancer Drug Targets, 14, 286-93. https://doi.org/10.2174/1568009614666140224155124
  25. McShane LM, Altman DG, Sauerbrei W, et al (2006). REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat, 100, 229-35. https://doi.org/10.1007/s10549-006-9242-8
  26. Nadir Y, Brenner B (2014). Heparanase multiple effects in cancer. Thromb Res, 133 Suppl 2, 90-4.
  27. Naomoto Y, Takaoka M, Okawa T, et al (2005). The role of heparanase in gastrointestinal cancer (Review). Oncol Rep, 14, 3-8.
  28. Pisano C, Vlodavsky I, Ilan N, et al (2014). The potential of heparanase as a therapeutic target in cancer. Biochem Pharmacol, 89, 12-9. https://doi.org/10.1016/j.bcp.2014.02.010
  29. QIN S-y, JIANG H-x, LI X (2007). Significance of bFGF, FGFR-2 and Hpa expression in gastric precancerous lesions and gastric carcinoma tissues. Chinese J Practical Internal Med, 17, 025.
  30. REN X-l, ZHU R-z, WANG L-j (2003). Clinicopathological significance of heparanase mRNA expression in gastric carcinoma. Chinese J Exp Surg, 9, 006.
  31. Takaoka M, Naomoto Y, Ohkawa T, et al (2003). Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest, 83, 613-22. https://doi.org/10.1097/01.LAB.0000067482.84946.BD
  32. Tang W, Nakamura Y, Tsujimoto M, et al (2002). Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol, 15, 593-8. https://doi.org/10.1038/modpathol.3880571
  33. Wang Z, Xu H, Jiang L, et al (2005). Positive association of heparanase expression with tumor invasion and lymphatic metastasis in gastric carcinoma. Mod Pathol, 18, 205-11. https://doi.org/10.1038/modpathol.3800282
  34. Wu BW, Li DF, Ke ZF, et al (2010). Expression characteristics of heparanase in colon carcinoma and its close relationship with cyclooxygenase-2 and angiogenesis. Hepatogastroenterol, 57, 1510-4.
  35. Xi Y, Zhang Y, Qi YJ, et al (2009). Expression of heparanase and CD105 in stomach neoplasm and its correlation. J Henan University, 3, 010.
  36. Zhang J, Yang J, Han X, et al (2012). Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy. Oncol Lett, 4, 178-82. https://doi.org/10.3892/ol.2012.703
  37. Zhang X, Xu S, Tan Q, et al (2013). High expression of heparanase-2 is an independent prognostic parameter for favorable survival in gastric cancer patients. Cancer Epidemiol, 37, 1010-3. https://doi.org/10.1016/j.canep.2013.09.012
  38. Sun YS, Ye ZY, a randomised (2005). The expression of heparanase protein in gastric cancer and its clinical significance. Zhejiang Med J, 644, 5-9.
  39. Wang ZhH, Wang YH, Jiang FT, et al (2008). The expressions and significances of heparanase in gastric cancer, paracancerous tissues and normal gastric tissue. Modern Med Oncol, 1953-5.
  40. Zhang L, Zhang X, Yang AJ, et al (2009). The expressions and significances of HPA and HIF-1 in gastric cancer. Shandong J Med Pharmcol, 89-90.
  41. Zheng ZHC, Wang SHB, Xu HM (2004). The expressions of heparanase and bFGF in gastric cancer and its relationship with invasion and metastasis of gastric cancer. Chinese J Clin Oncol, 31, 4-8.

Cited by

  1. Oleuropein represses the radiation resistance of ovarian cancer by inhibiting hypoxia and microRNA-299-targetted heparanase expression vol.8, pp.8, 2017, https://doi.org/10.1039/C7FO00552K
  2. MicroRNA-1258: An invasion and metastasis regulator that targets heparanase in gastric cancer vol.13, pp.5, 2017, https://doi.org/10.3892/ol.2017.5886